Cargando…

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma

Malignant mesothelioma (MMe) is a rare but aggressive malignancy. Although the molecular genetics of MMe is known, including BRCA1-associated protein-1 (BAP1) gene alterations, the prognosis of MMe patients remains poor. Here, we generated BAP1 knockout (BAP1-KO) human mesothelial cell clones to dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karnan, Sivasundaram, Ota, Akinobu, Murakami, Hideki, Rahman, Md. Lutfur, Wahiduzzaman, Md, Hasan, Muhammad Nazmul, Vu, Lam Quang, Hanamura, Ichiro, Inoko, Akihito, Riku, Miho, Ito, Hideaki, Kaneko, Yoshifumi, Hyodo, Toshinori, Konishi, Hiroyuki, Tsuzuki, Shinobu, Hosokawa, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362017/ https://www.ncbi.nlm.nih.gov/pubmed/37479714 http://dx.doi.org/10.1038/s41420-023-01552-5

Ejemplares similares

Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2020)

Establishment and characterization of CRISPR/Cas9‐mediated NF2 (−/−) human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma
por: Wahiduzzaman, Md, et al.
Publicado: (2018)

Experimental strategies to achieve efficient targeted knock-in via tandem paired nicking
por: Rahman, Md. Lutfur, et al.
Publicado: (2021)

Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
por: Yamaji, Masayuki, et al.
Publicado: (2017)

Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells
por: Kanasugi, Jo, et al.
Publicado: (2020)

Flow cytometry-based quantification of targeted knock-in events in human cell lines using a GPI-anchor biosynthesis gene PIGP
por: Rahman, Md. Lutfur, et al.
Publicado: (2021)

Flow cytometry-based quantification of genome editing efficiency in human cell lines using the L1CAM gene
por: Hasan, Muhammad Nazmul, et al.
Publicado: (2023)

Novel Interleukin-6 Inducible Gene PDZ-Binding Kinase Promotes Tumor Growth of Multiple Myeloma Cells
por: Ota, Akinobu, et al.
Publicado: (2020)

Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma
por: Kondo, Sayuri, et al.
Publicado: (2020)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
por: Karnan, Sivasundaram, et al.
Publicado: (2021)

Improved methods of AAV-mediated gene targeting for human cell lines using ribosome-skipping 2A peptide
por: Karnan, Sivasundaram, et al.
Publicado: (2016)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Simple Monitoring of Gene Targeting Efficiency in Human Somatic Cell Lines Using the PIGA Gene
por: Karnan, Sivasundaram, et al.
Publicado: (2012)

A Comparative Analysis of Constitutive Promoters Located in Adeno-Associated Viral Vectors
por: Damdindorj, Lkhagvasuren, et al.
Publicado: (2014)

Δ40p53α suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells
por: Ota, Akinobu, et al.
Publicado: (2017)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

Cytotoxicity of Callerya speciosa Fractions against Myeloma and Lymphoma Cell Lines
por: Lam, Vu Quang, et al.
Publicado: (2022)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens
por: Yamanaka, Shunpei, et al.
Publicado: (2023)

Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma
por: Onda, Maho, et al.
Publicado: (2023)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

De novo variants in CAMK2A and CAMK2B cause neurodevelopmental disorders
por: Akita, Tenpei, et al.
Publicado: (2018)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma
por: Amelio, Ivano
Publicado: (2017)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pakrh1dhtsn45ru4pqdunh2den